ArticlePPAR research2026
Serum Metabolomic Profiling Reveals Potential Mechanisms and Biomarkers of Seladelpar Treatment in Patients With Primary Biliary Cholangitis.
Article in PPAR research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seladelpar, a potent and selective peroxisome proliferator-activated receptor- Methods: Untargeted serum metabolomic analyses were conducted using UHPLC-MS/MS on fasting samples from 160 patients with PBC, collected before and after 12 weeks of treatment with placebo ( Results: A total of 1474 metabolites were identified from global untargeted serum metabolomics analysis. Random forest, weighted correlation network analysis, and differential abundance analysis revealed significant metabolomic changes after seladelpar treatment. Notable changes included significant increases in carnitine, acetylcarnitine, other acylcarnitines, and branched-chain amino acid catabolites as well as significant decreases in dicarboxylates, saturated and unsaturated fatty acids, and lipid-derived inflammatory mediators including ceramides. Targeted metabolomics confirmed seladelpar's impact on carnitine and acylcarnitines, which facilitate fatty acid Conclusions: Seladelpar treatment of PBC patients resulted in broad changes in serum metabolites, many of which are downstream of known PPAR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.